Kamunting Street Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Kamunting Street Capital Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,000	Closed	-$1.09M	–	51
2019 Q2	$1.09M	Buy	+10,000	New	+$1.06M	1.07%	20

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Kamunting Street Capital Management's IBB Position: Q3 2019 in Review

Kamunting Street Capital Management sold out of iShares Biotechnology ETF (IBB) in Q3 2019, closing a stake of 10,000 shares — an estimated $1.09M sold.

Kamunting Street Capital Management first reported a position in IBB in Q2 2019 and held it in 1 quarter. The position peaked at $1.09M in Q2 2019. 597 funds tracked by Wall St. Rank hold IBB as of Q3 2019.

Kamunting Street Capital Management reported no remaining iShares Biotechnology ETF position as of Q3 2019 after selling out during the quarter.
Kamunting Street Capital Management sold 10,000 iShares Biotechnology ETF shares in Q3 2019, an estimated $1.09M.
Kamunting Street Capital Management first reported a position in iShares Biotechnology ETF in Q2 2019 and held it in 1 quarter.
Kamunting Street Capital Management's iShares Biotechnology ETF position peaked at $1.09M in Q2 2019.
597 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2019.

Based on Kamunting Street Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.